Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brainsway ( (BWAY) ) has provided an announcement.
On December 22, 2025, BrainsWay Ltd. reported that Optum Behavioral Health, part of UnitedHealth Group and covering more than 48 million lives, has expanded its medical policy to include insurance coverage for BrainsWay’s Deep TMS therapy for adolescents aged 15 and older diagnosed with major depressive disorder. The move aligns Optum with a growing roster of major insurers—including Evernorth, CVS/Aetna, Medi-Cal, TRICARE, multiple Blue Cross Blue Shield plans and others—that now collectively cover about 180 million lives for adolescent Deep TMS depression therapy, potentially broadening access to a non-drug, clinically validated treatment option for a large and underserved adolescent population facing major depression in the U.S.
The most recent analyst rating on (BWAY) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s overall stock score is driven by strong financial performance and positive earnings call insights, indicating robust growth and strategic progress. However, the high valuation and technical indicators suggest caution, balancing the optimistic outlook with potential risks.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a global medical technology company specializing in advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform is FDA-cleared for major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies. Founded in 2003 and operating in the United States and Israel, BrainsWay focuses on expanding clinical evidence and market access for Deep TMS across psychiatric, neurological and addiction indications.
Average Trading Volume: 63,720
Technical Sentiment Signal: Buy
Current Market Cap: $323.8M
See more insights into BWAY stock on TipRanks’ Stock Analysis page.